Novartis has scooped one of the top 2016 UK Prix Galien Awards, considered to be the highest accolades that can be awarded to a pharmaceutical product.
The Innovative Product Award was given to its heart failure treatment, Entresto (sacubitril/valsartan), the first new treatment for the condition in 15 years, Novartis’ fourth UK Prix Galien medal since 2002.
Chiesi’s Holoclar and Astellas’ Dificlir were also recognised at the ceremony, which was held at the House of Commons in London on 21 September 2016.
Chiesi’s Holoclar — Europe’s first approved stem cell therapy for moderate-to-severe forms of limbal stem cell deficiency (LSCD), a rare eye condition that can lead to blindness — was given the Orphan Product Award.
Astellas was awarded a Real World Evidence Award for its Clostridium difficile treatment, Dificlir (fidaxomicin), which launched in 2012 and received a previous Prix Galien commendation in 2014.
Prix Galien Awards take place in 17 countries across the world and there is an international event every two years, but this year the UK was the first country to issue the Real World Evidence Award.
Sir Michael Rawlins, chair of the UK Prix Galien judging panel, comments: “A unique series of local service evaluations were conducted in 2013—2014 to evaluate the impact of Dificlir introduction on the NHS. The evaluation, studied in real-world settings, included investigating its effects on service delivery, the management of CDI and its costs, primarily to inform local decision-making.
“Results indicated the very significant contribution that Dificlir’s use can make to tackling the major public health problems of antimicrobial resistance through targeted antibiotic therapy and infection control,” he adds.
The 2016 UK awards received a record number of entrants, 16 of which were shortlisted.
The Prix Galien was created in France in 1970 by pharmacist Roland Mehl to promote advances in pharmaceutical research.